Immunotherapy before surgery may cut skin cancer recurrence

NCT ID NCT04808999

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This trial tests whether giving the immunotherapy drug pembrolizumab (Keytruda) before surgery can improve outcomes for people with high-risk cutaneous squamous cell carcinoma (cSCC), a common skin cancer. Participants receive pembrolizumab infusions before their planned surgery, and researchers track how the cancer responds and whether it returns. The goal is to see if this neoadjuvant approach reduces the risk of relapse in patients who have not previously received PD-1 inhibitors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pembrolizumab (Keytruda), an immunotherapy drug that helps the immune system fight cancer
What this could lead to
If successful, this approach could offer a way to reduce the risk of cancer returning after surgery for high-risk skin cancer.
What could go wrong
This is a small, early-phase trial, so results may not apply broadly. Immunotherapy can cause side effects like inflammation in healthy organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.